OmniAb Inc

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. The firm’s platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OmniAb Inc reports robust Q4 earnings, poised for biotech innovation

OmniAb Inc delivered strong financial performance in Q4 2022, showcasing revenue growth and a healthy cash position. The company's focus on innovation, diverse platform, and strategic partnerships position them for continued success. While challenges like partner retention and funding concerns exist, OmniAb's strengths in technology and commitment to discovery present significant opportunities for growth.
With a strong capital position, OmniAb is well-equipped to navigate challenges and capitalize on opportunities in the biotech space. The company's emphasis on internal technology development, strategic acquisitions, and employee engagement underscores a proactive approach to sustaining leadership in antibody discovery. By leveraging their strengths and seizing opportunities, OmniAb is poised for future growth and market differentiation.
OmniAb's commitment to innovation, diverse platform, and strong capital position set the stage for continued success in antibody discovery. Challenges such as partner retention and funding uncertainties require strategic navigation. By focusing on technology development, strategic partnerships, and employee motivation, OmniAb can overcome challenges and leverage opportunities for sustained growth and market leadership.

OmniAb Inc reports strong revenue growth and strategic milestones

OmniAb Inc's Q1 2023 performance reflects robust revenue growth, strategic milestones, and a commitment to innovation in antibody discovery and development.
The company's strengths lie in its diverse host systems, proprietary platforms, strong partnerships, and scalable business model, positioning it for continued success.
While facing challenges in operational clarity and industry funding cycles, OmniAb has opportunities to drive growth through M&A, investments, and engagement with stakeholders.

OmniAb Inc reports revenue growth and strategic partnerships in Q2

OmniAb Inc's Q2 performance reflects revenue growth from new partnerships and a strong financial position with significant cash reserves
The company's technology strengths lie in its diverse host systems, successful partnerships, and innovative AI-driven tools for antibody discovery
While facing challenges like market headwinds and attrition rates, OmniAb sees opportunities in academic partnerships, regulatory changes, and ion channel programs

OmniAb Inc reports growth in partnerships but faces revenue challenges

OmniAb Inc showed growth in partnerships and programs but faced challenges with revenue and expenses in 2023.
The company's strengths lie in successful product launches, new partnerships, and a strategic focus on revenue growth sources.
Opportunities for growth include advancements in programs, lower cash use projections, and investments in new technologies.
Addressing challenges like revenue fluctuations and market uncertainties will be crucial for OmniAb's future success.

OmniAb Inc reports revenue growth and pipeline strength in Q1

OmniAb Inc's Q1 2024 performance showcased revenue growth and strong partnership developments, despite a net loss.
The company's pipeline strength, progress in clinical trials, and financial stability are key strengths driving future prospects.
Challenges include managing expenses, partner decisions impacting programs, and maintaining cash usage levels for growth initiatives.
Opportunities lie in expanding partnerships, advancing pre-clinical programs, exploring new collaborations, and leveraging positive market outlook.

OmniAb Inc reports robust Q3 performance with growth opportunities

OmniAb Inc showcased strong operational performance in Q3 2024, marked by growth in partners, programs, and potential milestones.
While facing challenges in achieving profitability and program terminations, the company's financial stability and industry collaborations position it well for future opportunities.
By focusing on innovation, strategic partnerships, and prudent financial management, OmniAb is poised to capitalize on its strengths and navigate challenges effectively.
Analyst inquiries highlighted areas of interest and potential scrutiny, indicating a need for continued transparency and strategic decision-making by OmniAb's leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

OmniAb, Inc. (NASDAQ:OABI ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Stephen Willey - Stifel Alex Xenakis - Truist Securities Jacqueline Kisa - TD Cowen Conor McNamara - RBC Capital Markets Operator Good afternoon, and welcome to OmniAb, Inc. Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript

OmniAb, Inc. (OABI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.16 per share a year ago.

OmniAb, Inc. (OABI) Reports Q3 Loss, Lags Revenue Estimates

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives an.

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19th. Jefferies London Healthcare Conference, November 19-21 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer.

OmniAb to Participate in Two Investor Conferences in November

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss third quarter financial results and business updates       Date:   Tuesday, November 12, 2024       Time:  .

OmniAb to Report Third Quarter 2024 Financial Results on November 12

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of September. H.C. Wainwright 26th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel. Management will deliver a corporate presentation on Tuesday, September 10th at 2:30 p.m. Eastern Time and will hold one-on-one meetings with investors. Craig-Hallum Bioprocessing Virtual Conference, September 19t.

OmniAb to Participate in Two Investor Conferences in September

OmniAb, Inc. (NASDAQ:OABI ) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference Call Participants Michael Sonntag - Leerink Partners Chad Wiatrowski - TD Cowen Stephen Willey - Stifel Conor McNamara - RBC Capital Markets Operator Good afternoon and welcome to OmniAb Incorporated 2024 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. “Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new partnerships and programs as existing partners made important clinical progress in their respective programs,” said Matt Foehr, Chief Executive Officer of OmniAb.

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

FTAI Infrastructure LLC

FTAI Aviation Ltd

Immunovant Inc

Latch

Purple Innovation

The RealReal

RCI Hospitality

In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 2000 remains a more appropriate benchmark for comparison. Top gainers include FTAI Aviation and FTAI Infrastructure, while top detractors include Latch and Industrial Short.

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Thursday, August 8, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Thursday, August 8, 2024       Time:   4:30 p.m. Eastern time (.

OmniAb to Report Second Quarter 2024 Financial Results on August 8

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journal of Immunology demonstrating that chickens can be genetically engineered to produce functional heavy chain-only single-domain antibodies. sdAbs are produced naturally by camelids and have gained popularity as small, robust and highly modular building blocks fo.

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived webcast of the presentation will be available in the Investors section of OmniAb's websit.

OmniAb to Participate in the Jefferies Global Healthcare Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today the Company presented an overview of xPloration, a high-throughput single B-cell screening platform that leverages machine learning and Artificial Intelligence (AI), in a presentation titled “Deep Screening in Harmony with Artificial Intelligence for Bispecific Antibod.

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

OmniAb, Inc. (NASDAQ:OABI ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Conference Call Participants Nishant Gandhi - Truist Securities Jack Siedow - Craig-Hallum Michael Sonntag - Leerink Partners Jacqueline Kisa - Cowen Operator Good afternoon and welcome to OmniAb Inc. First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new platform license agreements in the first quarter, bringing our total active partners to 80, net of attrition,” said Matt Foehr, Chief Executive Officer of O.

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May. RBC Capital Markets Global Healthcare Conference, May 14-15 at the InterContinental Barclay Hotel in New York City. Management will participate in a fireside chat on Wednesday, May 15th at 11:30 a.m. Eastern time and will hold one-on-one meetings with investors. A live and archived webcast of the fireside chat will be availa.

OmniAb to Participate in Five Investor Conferences in May

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Thursday, May 9, 2024       Time:   4:30 p.m. Eastern time (1:30 p.m. Pac.

OmniAb to Report First Quarter 2024 Financial Results on May 9

Tharimmune Inc

Group includes leading experts in multiple disciplines including immunology, liver diseases, protein engineering, antibody drug conjugates and platform innovation BRIDGEWATER, NJ / ACCESSWIRE / April 15, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology announced today the formation of a new Scientific Advisory Board (SAB) that includes a group of leading experts in fields spanning immunology, liver disease clinical trials, protein engineering, antibody drug conjugates as well as Knob domains, the smallest antibody like fragments. "Tharimmune's mission is to advance immunology and oncology treatments for people suffering from high unmet need conditions and help them look forward to a better tomorrow," said Randy Milby, Chief Executive Officer of Tharimmune.

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

OmniAb, Inc. (OABI) Q4 2023 Earnings Call Transcript

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. “2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, while key partner programs made significant progress despite last year's sector-related headwinds. Partners exceeded our expectations regarding the number of.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

OmniAb, Inc. (OABI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:   OmniAb conference call to discuss financial results and business updates       Date:   Wednesday, March 20, 2024       Time:   4:30 p.m. Eastern t.

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March. TD Cowen 44th Annual Healthcare Conference, March 4-6, 2024, at the Marriott Copley Place in Boston, MA. Management will participate in a fireside chat on Monday, March 4th at 11:10 a.m. Eastern time and will be available for one-on-one meetings with investors. Leerink Partners Global Biopharma Conference, March 11-13, 2024, at the.

OmniAb to Participate in Two Investor Conferences in March

Archer Aviation

Compass Minerals

Green Plains

Planet Labs

Talos Energy Inc

Utz Brands

While your typical financial advisor will likely direct you to focus on established blue chips to boost your holdings, few other compelling options exist other than powerful small-cap stocks. To be 100% clear, entities that offer significant upside reward potential usually carry significant risks.

Mighty Minis: 7 Small-Cap Stocks That Punch Above Their Weight

EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific data on its OmnidAb™ platform, the industry's first and only transgenic chicken host system producing single domain antibodies (sdAbs), at the 2023 Antibody Engineering & Therapeutics Conference underway in San Diego and hosted by The Antibody Society. The Company presented an overview of OmnidAb and its functionality to industry leaders and prospective customers today in a presenta.

News for OmniAb Inc Stock (OABI)